Finally, our group has shown that inhibiting the TGFβ pathway at multiple levels using inhibitors of the TGFβ ligands, the TGFβ receptors, and TGFβ transducers (such as SMAD3) improves hematopoiesis in FA preclinical models. The gene discussed is SMAD3; the disease is Friedreich ataxia.